**Author details**

Shyamika Mirisse Acharige\* and Chit Cheng Yeoh\* Queen Alexandra Hospital, Portsmouth, United Kingdom

\*Address all correspondence to: shyamika.acharige@porthosp.nhs.uk and chitcheng.yeoh@porthosp.nhs.uk

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**33**

*Ovarian Cancer Genetics and the Implications DOI: http://dx.doi.org/10.5772/intechopen.96488*

[1] Jenna Lilyquist,a,b Holly LaDuca,c Eric Polley,b Brigette Tippin Davis,c Hermela Shimelis,a Chunling Hu,a Steven N. Hart,b Jill S. Dolinsky,c Fergus J. Couch,a,b and David E. Goldgar Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multigene panels compared to reference controls Science direct 2017 doi: 10.1016/j.ygyno.2017.08.030

Familial and Sporadic Greek Ovarian Cancer Cases Published: March 11, 2013 PLOS ONE https://doi.org/10.1371/

[7] Andre jDudáš Miroslav Chovanec DNA double-strand break repair by homologous recombination Mutation research/reviews https:// www.sciencedirect.com/science/

[8] M. Moschetta, A. George, S.B. Kaye, S. Banerjee BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer 2016 Annals of oncology PMID: 27037296 DOI: 10.1093/

[9] Kiyotsugu Yoshida Yoshio Miki Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage First published: 19 August 2005 Onlinelibrary.wiley.com https://doi. org/10.1111/j.1349-7006.2004.tb02195.x

[10] Kathleen N. Moore, Mansoor Raza Mirza, Ursula A. Matulonis The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities Gynaecologic Oncology 2018 PMID: 29397193 DOI: 10.1016/j.

[11] *Robert T. Neff, Leigha Senter, Ritu Salani BRCA* mutation in ovarian cancer: testing, implications and

[12] Clinical Comissioning Policy: Genetic Testing for BRCA1 and BRCA2

[13] U.S National Library of Medicine information on inherited diseases.

[14] Colombo N, Nicoletto M, Benedetti Panici P, et al Combination Cediranib

treatment considerations First Published June 19, 2017 SAGE Journals https://doi. org/10.1177%2F1758834017714993

journal.pone.0058182

journal/13835742 2004

annonc/mdw142

ygyno.2018.01.011

2015 NHS England.

[2] Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 2007;

[3] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA* 2017; 317(23):2402-2416.[PubMed Abstract]

[4] Robert J Kurman 1, Ie-Ming Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory 2010 National Library of Medicine NIH PMID: 20154587 PMCID: PMC2841791 DOI: 10.1097/

[5] Maise Al Bakir, Hani Gabra The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future *British Medical Bulletin*, Volume 112, Issue 1, December 2014, Pages 57-69, https://doi.

org/10.1093/bmb/ldu034 Published:02

[6] Alexandra V. Stavropoulou,Florentia Fostira,Maroulio Pertesi,Marianthi Tsitlaidou,Gerassimos E. Voutsinas,Olga

Bamias,Meletios A. Dimopoulos,Eleni

Christodoulou,George Klouvas,Christos Papadimitriou, Irene Konstantopoulou Prevalence of BRCA1 Mutations in

Triantafyllidou,Aristotelis

Timotheadou,Dimitrios Pectasides,Christos

PAS.0b013e3181cf3d79

December 2014

**References**

25(11):1329-1333.

*Ovarian Cancer Genetics and the Implications DOI: http://dx.doi.org/10.5772/intechopen.96488*
